Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Oncoinvent

Oncoinvent Announces Publication of 18-Month Safety and Efficacy Data from the Phase 1/2a Study of Radspherin® in Colorectal Cancer
From Oncoinvent
Via Business Wire
Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients
From Oncoinvent
Via Business Wire
Oncoinvent appoints Anders Månsson as CEO
From Oncoinvent
Via Business Wire
Oncoinvent to Present at TD Cowen Radiopharmaceutical Innovation Summit
From Oncoinvent
Via Business Wire
Oncoinvent to Present at Guggenheim Radiopharmaceuticals Day
From Oncoinvent
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.